Pulsenmore Ltd. (TLV:PULS)
Israel · Delayed Price · Currency is ILS · Price in ILA 429.90
+54.90 (14.64%)
Aug 24, 2025, 3:50 PM IDT
Pulsenmore Revenue
In the year 2024, Pulsenmore had annual revenue of 9.66M ILS with 56.12% growth. Pulsenmore had revenue of 5.31M in the half year ending December 31, 2024, a decrease of -28.82%.
Revenue
9.66M
Revenue Growth
+56.12%
P/S Ratio
22.51
Revenue / Employee
166.57K
Employees
58
Market Cap
217.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.66M | 3.47M | 56.12% |
| Dec 31, 2023 | 6.19M | -4.63M | -42.78% |
| Dec 31, 2022 | 10.81M | 9.24M | 585.30% |
| Dec 31, 2021 | 1.58M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 56.02B |
| Danel (Adir Yeoshua) | 2.84B |
| Kamada | 571.15M |
| Bait Bakfar | 104.50M |
| SofWave Medical | 234.12M |
| BrainsWay | 155.27M |
| Novolog (Pharm-Up 1966) | 2.09B |
| Ilex Medical | 922.54M |